CIP
PCRX icon

Convergence Investment Partners’s Pacira BioSciences PCRX Stock Holding History

Convergence Investment Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,010
Closed -$174K – 343
2019
Q2 		$174K Buy
+4,010
New +$170K 0.04% 270
2015
Q3 		– Sell
-3,406
Closed -$241K – 393
2015
Q2 		$241K Sell
3,406
-5,534
-62% -$436K 0.02% 334
2015
Q1 		$794K Sell
8,940
-14,592
-62% -$1.48M 0.11% 283
2014
Q4 		$2.09M Buy
23,532
+3,417
+17% +$323K 0.28% 131
2014
Q3 		$1.95M Buy
+20,115
New +$1.96M 0.27% 143

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return